4.4 Article

Optimising Medications for Patients With Cancer and Multimorbidity: The Case for Deprescribing

期刊

CLINICAL ONCOLOGY
卷 32, 期 9, 页码 609-617

出版社

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2020.05.015

关键词

Clinical oncology; deprescribing; multimorbidity and cancer; polypharmacy; potentially inappropriate medications

类别

资金

  1. Canadian Institutes of Health Research grant [201410PHE-PHE-337814e96399]
  2. MITACS Elevate fellowship [IT11649]
  3. Blue Cross/Blue Shield
  4. Cancer Prevention and Research Institute of Texas
  5. National Breast Cancer Foundation in Australia

向作者/读者索取更多资源

The majority of patients diagnosed with cancer are aged over 65 years and have two or more chronic conditions in addition to cancer and the risk of chronic conditions increases further after cancer. The presence of multimorbidity adds complexity to care, as patients' goals of care and the focus of treatment can change with a diagnosis of cancer. Multimorbidity is frequently associated with polypharmacy, the use of potentially inappropriate medications, the presence of adverse drug reactions and potential drug-drug interactions: all of which impact on health outcomes and the cost of care. Consequently, it is vital that a systematic approach is taken to regularly review cancer patients' medication regimens to ensure that they support an optimal balance of benefits with acceptable levels of harm. Several patient and clinician resources are presented to guide the process of medication review and deprescribing. (C) 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据